AstraZeneca may face a fine of up to $8 million in China over suspected unpaid taxes related to the import of its breast cancer drug Enhertu, the drugmaker said on Tuesday, as it works to revive business in its second-biggest market after scandals.

On Feb. 7, AstraZeneca announced it received a Notice of Transfer to the Prosecutor and an Appraisal Opinion from the Shenzhen City Customs Office regarding suspected unpaid importation taxes of USD900,000 in January, with the firm facing a fine of up to USD4.5 million. The import taxes relate to oncological drugs Imfinzi and Imjudo, it added.

AstraZeneca (NASDAQ: NASDAQ:AZN) said Tuesday it could be fined up to $8 million by Chinese authorities over allegedly unpaid import taxes. Concerning the illegal drug importation allegations, AstraZeneca received an appraisal opinion from the Shenzhen City Customs Office regarding suspected unpaid importation taxes amounting to $1.